Exin founder reports AI-controlled brain injection in a live mouse

Image: Primary

Published Saturday, October 31, 2026 · 7:05 AM EDT

An AI agent controlled a robotic brain injection in a living mouse, Exin Therapeutics cofounder Gabriel Ocana Santero told WIRED. The agent selected a treatment from 19 options, chose the brain region and injection coordinates, and controlled injection volume and speed after a veterinary surgeon performed the craniotomy. The team used Claude Sonnet 5 after Claude Opus 5.5 refused to proceed. Humans approved the injection plan and retained an emergency motor cutoff. A coordinate-system glitch required code changes by a separate agent, extending a procedure that typically takes about 45 minutes to slightly longer than an hour. The team is waiting to assess the therapy's effect on seizures.

Sources

WIRED

In this story

Anthropic

Published by Tech & Business, a media brand covering technology and business. This story was sourced from WIRED and reviewed by the T&B editorial agent team.

Back to Newswire

Keep reading

Full wire

AI Science

GARDEN preprint demonstrates reusable AI-designed rewards for cooperating agents

Researchers report in a preprint that GARDEN, a system that uses a language model to design rewards for cooperating agents, improved performance when its reward programs transferred unchanged to related scenarios unseen during design.

Products Policy

Binance seeks licensed return to Malaysia through regulatory talks

Binance said it is discussing a licensed business in Malaysia with the country's regulators. The cryptocurrency exchange is seeking a route back into a market where authorities have blocked its website and applications. The discussions concern access through a licensed operation.

AI Science

AgenticDS preprint reports better training-data search and downstream accuracy

Researchers report that AgenticDS, a framework for finding model training datasets, improved search ranking quality and downstream training accuracy in a new preprint.

AI Science

KARMA preprint reports advertising-agent gains without model retraining

A KARMA preprint reports improved advertising-agent performance by editing decision knowledge while keeping model weights and executable code fixed.

Infrastructure AI

CoreWeave, Nebius and Nscale reportedly lose effective bond market access

CoreWeave, Nebius and Nscale have effectively been shut out of the bond market in recent weeks, The Wall Street Journal reported, citing sources.

AI Science

Insilico says AI-discovered Rentosertib has entered Phase III trials

Insilico Medicine says Rentosertib, its generative AI-discovered drug candidate also known as ISM001-055, has entered Phase III clinical trials for idiopathic pulmonary fibrosis. The company described the clinical advance in an announcement carried by News-Medical.Net.